Logo for Acasti Pharma Inc

Acasti Pharma Investor Relations Material

Latest events

Logo for Acasti Pharma Inc

Q3 2023

Acasti Pharma
Logo for Acasti Pharma

Q1 2025

9 Aug, 2024
Logo for Acasti Pharma

Q4 2024

21 Jun, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies

Latest reports from Acasti Pharma Inc

Access all reports
Acasti Pharma Inc., is an Canadian biopharmaceutical company that engages in the development and commercialization of pharmaceutical products for the treatment of dyslipidemia and cardiometabolic risk factors. Its lead drug candidate, CaPre, is a prescription-only medication for the treatment of hypertriglyceridemia. It offers CoregCR, a registered therapeutic formulation of carvedilol for the treatment of hypertension and heart failure for patients with chronic renal impairment.